Steven L. Hoerter - Feb 14, 2023 Form 4 Insider Report for Deciphera Pharmaceuticals, Inc. (DCPH)

Role
President and CEO, Director
Signature
/s/ Jeffrey M. Held, Attorney-in-Fact
Stock symbol
DCPH
Transactions as of
Feb 14, 2023
Transactions value $
-$480,720
Form type
4
Date filed
2/16/2023, 03:18 PM
Previous filing
Jun 17, 2022
Next filing
Mar 23, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DCPH Common Stock Sale -$481K -30K -80.02% $16.00 7.5K Feb 14, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DCPH Stock Option (Right to Buy) Award $0 +250K $0.00 250K Feb 15, 2023 Common Stock 250K $15.48 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale of shares reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 14, 2022.
F2 This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in equal monthly installments over four (4) years, beginning on March 15, 2023.